Background--Patients with stable coronary heart disease (CHD) have widely varying prognoses and treatment options. Validated models for risk stratification of patients with CHD are needed. We sought to evaluate traditional and novel risk factors as predictors of secondary cardiovascular (CV) events, and to develop a prediction model that could be used to risk stratify patients with stable CHD.
A n estimated 15.5 million adults in the United States live with coronary heart disease (CHD). 1 With advances in the treatment of acute coronary syndromes and aggressive risk factor management, patients now live longer with chronic CHD, and secondary prevention has become a major focus. 2 To date, predicting risk of secondary events has received little attention because all patients with stable CHD are recommended to receive similar treatment with lipid-lowering medications, antiplatelet agents, b-blockers, angiotensin inhibitors, smoking cessation, and glycemic control, regardless of disease severity. However, given the widely varying prognoses 3 and expanding range of therapeutic options for patients with chronic CHD, such as novel antiplatelet agents and revascularization procedures, it has become increasingly necessary to define distinct risk groups for whom different treatment strategies may be preferred. 4 Most cardiovascular (CV) risk models have focused on predicting incident CHD 5, 6 or outcomes after acute coronary syndromes. 7 In these models, traditional risk factors, such as age, gender, smoking, hypertension, cholesterol, and diabetes, have remained the cornerstone of risk stratification. 8 However, it is increasingly recognized that risk factors for incident CHD may not predict secondary events in patients with prevalent CHD, in part because better risk factor profiles may reflect more aggressive control of sicker patients. 9 Once clinical CHD exists, markers of end-organ damage may be more important than risk factors for incident disease. Thus, new approaches for risk prediction in patients with stable CHD are needed. Many novel risk factors have been shown to provide incremental prognostic information in patients with stable CHD. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Likewise, combining traditional risk factors with symptom severity, ejection fraction, and standard laboratory test results can improve prediction of secondary events. [20] [21] [22] [23] [24] [25] [26] [27] However, unlike the Framingham risk score for developing incident CHD, the few existing secondary prevention models have not become widely accepted for use in clinical practice, 19, 20, 22, 23, 27 in part because of model complexity and lack of external validation. Simple integrated prediction models that capture risk of secondary events are lacking. Our objectives were to evaluate traditional risk factors and novel biomarkers as predictors of 5-year risk of secondary events, and to develop a prediction model that could be used to risk stratify patients with chronic stable CHD.
Methods

Derivation Cohort
The Heart and Soul Study is a prospective cohort study that was originally designed to investigate the effect of psychosocial factors on prognosis in patients with stable CHD. Methods have been previously described. 28 Subjects were eligible if they met one of the following criteria: (1) history of myocardial infarction, (2) history of coronary revascularization, (3) ≥50% angiographic stenosis in at least 1 coronary artery, or (4) exercise-induced ischemia by treadmill ECG or nuclear perfusion imaging. Exclusion criteria were the following: (1) history of myocardial infarction within the past 6 months, (2) inability to walk 1 block, or (3) intention to move out of the local area within 3 years. The protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent. Between September 2000 and December 2002, 1024 participants enrolled and completed a baseline study visit that included an interview, questionnaire, 12-hour fasting blood draw, and echocardiogram. Serum was stored at À70°C. The current analysis was restricted to the 912 participants with complete baseline data. The last date of follow-up was June 14, 2011.
Model Covariates
Eighteen candidate predictors were chosen based on clinical judgment, prior literature, and reproducibility of tests (Table 1) . Age, sex, current smoking, medication use, history of myocardial infarction, and history of heart failure were collected by self-report questionnaire. Diabetes was defined by self-report, fasting glucose ≥126 mg/dL, or taking diabetic medications. Hypertension was defined by selfreport, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg. Blood pressure was measured by trained study personnel using calibrated sphygmomanometers. Body mass index was calculated as weight in kilograms divided by height in meters squared. Left ventricular ejection fraction was measured by echocardiography. Physical activity and medication adherence were assessed by self-report. 28, 29 Estimated glomerular filtration rate was calculated using the combined (serum creatinine and cystatin C) CKD-Epi equation. 30 Urinary albumin and creatinine were measured from 24-hour urine collections by nephelometry and the rate Jaffe method, respectively, and urinary albumin to creatinine ratio (uACR) was calculated as milligrams of albumin divided by grams of creatinine. Fasting total and high-density lipoprotein (HDL) cholesterol were measured, and low-density lipoprotein cholesterol was calculated by the Friedewald equation. High-sensitivity C-reactive protein was measured by the Roche Integra assay or the Beckman Extended Range assay. Results from these 2 assays were highly correlated (r=0.99). High-sensitivity cardiac troponin T (hs-cTnT) was measured using highly sensitive reagents on an Elecsys 2010 analyzer (Roche Diagnostics). 31 N-terminal pro-type brain natriuretic peptide (NT-proBNP) was measured with the Roche Elecsys NT-proBNP assay.
Outcome Variables
The composite outcome variable was time to first nonfatal myocardial infarction, stroke, or CV death. Annual telephone interviews with participants or their proxies were conducted regarding recent emergency room visits, hospitalizations, or death. For any reported event, 2 independent and blinded adjudicators reviewed medical records, ECGs, death certificates, and coroner's reports. If the adjudicators agreed on the outcome classification, their classification was binding. If they disagreed, a third blinded adjudicator reviewed the event and determined the outcome classification. Nonfatal myocardial infarction and stroke were defined using standard criteria. 32, 33 CV death was defined as due to myocardial infarction, sudden death, heart failure, coronary revascularization, stroke, or peripheral vascular disease.
External Validation Cohort
We are not aware of any other prospective observational cohort study of patients with stable CHD that has measured all 3 biomarkers (uACR, troponin, and NTproBNP) that were selected in our derivation sample. However, the PEACE trial was a randomized trial of trandolapril versus placebo in 8290 patients with stable CHD and left ventricular ejection fraction >40% who were enrolled from November 1996 to June 2000 and were followed for up to 7 years (median 4.8 years) (last date of follow-up December 31, 2003) . 34 Of these, 2876
participants had measurements of smoking status, NT-proB-NP, hs-cTnT, and uACR, as well as detailed adjudication of CV events (urine samples for uACR were available for only 2977 participants. Additionally, 80 were excluded due to lack of serum biomarker measurements, 3 due to lack of smoking status, and 8 due to lack of follow-up). 11, 16, 35, 36 Statistical Analysis
Cox proportional hazards models were developed for risk stratification. At the outset, we omitted the 4 weakest predictors-low-density lipoprotein, high-density lipoprotein (HDL), prior history of myocardial infarction, and hypertension (all P-values >0.5). We then exhaustively screened candidate models with 4 to 11 predictors and potential interactions using 20 repetitions of 10-fold cross-validation of Harrell's C-index, a measure of discrimination. 37 Internal cross-validation was used to minimize overfitting. Nonnormal continuous variables were log-transformed to improve linearity. After the model selection algorithm was run, we selected the top 4-predictor model based on crossvalidated C-index (CVCI). Although they had slightly better discrimination (higher C-indices), models incorporating more than 4 predictors included predictors that were not independently associated with CV events in multivariate models. Including additional variables did not meaningfully improve C-index or calibration. Calibration was assessed by visual comparison of observed and model-based risk by decile of model-based risk and informal comparison of the average model-based 5-year event risk with nonparametric Kaplan-Meier estimates. We also assessed model fit with a likelihood ratio test for addition of deciles of model-based risk to the continuous model. In addition, we evaluated the cross-validated calibration slope 38 as a measure of overfitting.
The Heart and Soul model was externally validated in 2876 participants from the PEACE trial. We calculated the C-index for the validation cohort and fitted 5-year risks using Cox model coefficients and 5-year baseline survival estimates from the derivation cohort.
To compare the relative strength of individual variables in the top model, we calculated standardized hazard ratios (per standard deviation increase in log-transformed variable), cross-validated C-indices for each variable alone, and net reclassification of each variable added to a base model containing the other 3 variables.
Category-free net reclassification improvement 39 was used to compare our model to the Framingham secondary events model for stable CHD. 19 To optimize performance of the Framingham model, we used a model in which coefficients for the Framingham predictor variables were refit to the derivation cohort. In the validation cohort, we substituted ln(total cholesterol) for ln(total cholesterol/HDL) because HDL was not measured, and re-estimated the coefficients of both models. We also compared the Framingham secondary events model and the Heart and Soul model C-indices in both derivation and validation cohorts, and estimated bootstrap confidence intervals using 500 repetitions. All statistical analyses were performed using STATA 11.0, 12.1, or 13.1 (Stata Corp, College Station, TX).
Results
The 912 participants in the Heart and Soul derivation cohort contributed 5979 person-years with a mean (SD) of 6.6 (2.8)
years follow-up. The 2876 participants in the PEACE validation cohort contributed 13 806 person-years with a mean (SD) of 4.8 (1.4) years follow-up. Compared to the derivation cohort, the validation cohort was significantly healthier at baseline (Table 1) and had lower annual rates of CV events (Table 2 ).
Discrimination
After screening for CVCI, the final model selected from the derivation cohort, the Heart and Soul risk model, contained, in order of importance: NT-proBNP, hs-cTnT, uACR, and current smoking. Larger models of up to 7 predictors only marginally improved discrimination, and even larger models beyond 7 predictors actually performed worse than the more parsimonious models. The 4-predictor Heart and Soul model had a CVCI of 0.73 (95% CI 0.69 to 0.76). Notably, traditional CV risk factors such as age, hypertension, low-density lipoprotein, diabetes, and obesity did not appear in the top predictive models. Including interactions between sex and other predictors did not increase the CVCI. Replacing NT-proBNP with BNP resulted in minimally changed CVCI of 0.73 (95% CI 0.69 to 0.76). We also performed a sensitivity analysis adding baseline medications (aspirin, b-blockers, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics) to the model, and did not find any improvement.
Calibration
Observed estimates of 5-year event incidence were similar to predicted risk (Figure -Panels A and B) in the derivation cohort. The likelihood-ratio goodness-of-fit P-value was 0.07, and the cross-validated calibration slope was 0.96, indicating acceptable fit.
External Validation
In the validation cohort, C-index was 0.65 (95% CI 0.61 to 0.68), the goodness-of-fit P-value was 0.13, and the 
Comparison of Individual Variables
Standardized hazard ratios for the 4 individual predictors in the Heart and Soul model showed that NT-proBNP was the strongest biomarker (Table 3) , followed by hs-cTnT and then uACR. The top model with 5 predictors included the 4 predictors in the Heart and Soul model with the addition of high-sensitivity C-reactive protein, but high-sensitivity C-reactive protein was not significantly associated with CV events after multivariable adjustment for NT-proBNP, hs-cTnT, uACR, and smoking (hazard ratio 1.11 per SD increase, 95% CI 0.97 to 1.27; P=0.15). The hazard ratios of all the biomarkers were weaker in the validation cohort compared to the derivation cohort. C-indices of each individual variable for prediction of CV events and net reclassification of each variable also showed consistent results in terms of relative strength of variables as well as weaker performance of the biomarkers in the validation cohort (Table 4) .
Comparison of Heart and Soul Model to Framingham (Traditional) Secondary Events Model
The Framingham secondary events model 19 contains age, diabetes, and ln(total cholesterol/HDL) for men, plus an additional 2 variables for women: ln(SBP) and smoking. There was a statistically significant improvement in C-index between the Framingham secondary events model and the Heart and Soul risk model in both cohorts. In the derivation cohort, the 19 Other risk models of up to 16 risk factors, including patient-reported symptoms, left ventricular ejection fraction, and standard laboratory measurements have been developed. [20] [21] [22] [23] [24] [25] [26] [27] However, most of these models are too complex for routine use, and only 1 has been externally validated. 27 Since prediction CV indicates cardiovascular; HR, hazard ratios; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; NT-proBNP, N-terminal pro-type brain natriuretic peptide; uACR, urine albumin to creatinine ratio. *Adjusted for other variables in the model. †
Per standard-deviation increase in log variable. model creation tends to result in optimistic estimates, external validation provides valuable information about the performance of a model. 40 Though we observed a lower C-index in the validation population with our model, an externally validated C-index of 0.65 is well within the range of other commonly used CV prediction models, such as the CHADS-2 model for predicting stroke in patients with atrial fibrillation (validated C-index 0.63 to 0.70) 41, 42 and the Thrombolysis in Myocardial Infarction risk score for predicting death and ischemic events in patients with unstable angina or non-ST elevation myocardial infarction (validated C-index 0.59 to 0.65). 7, 43 Furthermore, even when we ran the selection algorithm on the PEACE cohort as if it were the derivation cohort, the highest CVCI was still <0.7. This suggests that the decrease in C-index in the validation cohort is less a reflection of overfitting, but rather that the general health and homogeneity of a clinical trial population makes it harder to risk stratify. Therefore, the decrease in discrimination is largely a reflection of PEACE being a healthier cohort of clinical trial subjects.
The inclusion of multiple novel risk factors in a risk model for secondary CV events represents a significant departure from previous risk models. Using both traditional and novel risk factors as candidate predictors, we found that the top model identified using a prespecified algorithm included only 1 traditional risk factor (smoking) and 3 novel risk factors (NTproBNP, hs-cTnT, uACR). It has been observed that the risk factors that predict a first event are often not the same factors that predict secondary events, possibly due to more aggressive treatment of traditional risk factors in diseased patients. 9 The participants included in this study were individuals with stable CHD, most of whom were receiving treatment for traditional risk factors, which may explain why traditional risk factors did not emerge as strong predictors of subsequent CV events. Biomarkers may provide more information about the burden of disease than traditional risk factors, including age. Notably, the novel risk factors identified as top predictors may reflect risk related to ongoing hemodynamic stress (NT-proBNP), myocardial damage (hs-cTnT), and renal dysfunction (uACR). In addition to improving overall risk estimation, measurement of novel risk factors could also play a role in directing intensification of therapies. In current practice, measurement of these novel risk factors is not routine, but there is interest in determining whether their use can improve clinical outcomes. Routine measurement of natriuretic peptides is gaining acceptance in the management of heart failure. 44 High-sensitivity troponin assays are not commercially available in the United States, but evidence of their utility in the setting of acute chest pain and risk prediction is strong. 12, 18, 45 Measurement of uACR is a recommended method for detecting chronic kidney disease and a Class IIa guideline recommendation in patients with CV disease because of their increased risk of concomitant kidney disease. 46, 47 Further study is needed to determine whether using a risk model based on multiple novel risk factors can improve clinical outcomes. Several limitations must be considered in the interpretation of our results. First, both the derivation and validation cohorts included 82% men, so future studies are required to test this model in cohorts with larger numbers of women. Second, HDL was not available in the validation cohort, and is a variable in the Framingham secondary events model; therefore we could not export the published coefficients directly from the Framingham model, and perform a true validation by category-free net reclassification improvement. Nevertheless, by refitting both models to the validation cohort, we were able to make a fair comparison of the performance of the variables themselves, confirming that novel markers were stronger than traditional risk factors in the validation cohort as well. Third, the drop in C-index from 0.73 in the derivation cohort to 0.65 in the validation cohort likely reflects differences in the cohorts, but could also reflect some degree of model overfitting. Fourth, this model was created in the context of the candidate predictors listed in Table 1 and does not account for any variation in risk that could occur due to other predictors not included in this analysis. Finally, like most CV risk prediction models, 48 this model does not take into account treatment effect during the course of follow-up. However, this model is meant to predict subsequent risk for stable and already well-treated CHD patients. In summary, we developed and validated a simple 4-predictor model for 5-year risk of CV events in patients with stable treated CHD. A risk model including multiple novel risk factors may be useful for estimating prognosis in patients with stable CHD to inform treatment decisions or for use as a risk stratification tool in future research.
